Boehringer Ingelheim is a top pharma company active in partnering, licensing and M&A in pharmaceuticals Read the full story

Boehringer Ingelheim announced over 120 partnering / licensing deals since 2005, with 18 deals in 2012 alone Read the full story

Boehringer Ingelheim has announced only 2 M&A deals since 2005, with the acquisition of SSP and Actimis Pharmaceuticals Read the full story

The Boehringer Ingelheim and European Foundation for the Study of Diabetes entered pharma deals to fund European-wide diabetes research. Read the full story

Boehringer Ingelheim, a big pharma company, have entered deals with pharma partners United BioSource for type 2 diabetes research. Read the full story

Valneva has entered biotech deals with Boehringer Ingelheim for the licensing of EB66 cell line for the development of animal health vaccines. Read the full story

Boehringer Ingelheim is a top pharmaceutical company based in Ingelheim, Germany Read the full story

Athera Biotechnologies has entered into pharma deals involving an option agreement with Boehringer Ingelheim on a novel preclinical antibody program. Read the full story

Boehringer Ingelheim, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years Read the full story

Humana and Boehringer Ingelheim, a big pharma company, announced a multi-year pharma partnering collaboration dedicated to improving health care and reducing costs for people affected by chronic obstructive pulmonary disease, cardiovascular disease, and other chronic disease states. Read the full story